Copyright © 2021. Inderes Oyj. All rights reserved.

Orion

Analyst

Antti Siltanen

Antti Siltanen

Analyytikko

Read more
Pauli Lohi

Pauli Lohi

Analyytikko

Read more

Yhtiön vuosikertomukset

Latest insider trading

Net impact profile

Tiedotteet
30.3.
2023

ORION CORPORATION                 PRESS RELEASE                 30 March 2023 at 9.30 EEST

Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines

Tiedotteet
27.3.
2023

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
27 MARCH 2023 at 09.00 EEST              
        

Comparative net sales data for 2022 under Orion's new organisational structure and revised accounting practice as of 1 January 2023

Tiedotteet
23.3.
2023

ORION CORPORATION
PRESS RELEASE
23 March 2023 at 15:00 EET              
        
Orion and Bayer expand clinical development program for darolutamide in prostate cancer

Tiedotteet
22.3.
2023

ORION CORPORATION
STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
22 MARCH 2023 at 17.15 EET              
        

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chair.

The compositions of the Board committees were decided to be as follows:

Tiedotteet
22.3.
2023

ORION CORPORATION
STOCK EXCHANGE RELEASE / DECISIONS OF GENERAL MEETING
22 MARCH 2023 at 16.30 EET              
        

Decisions taken by Orion Corporation’s Annual General Meeting on 22 March 2023

At the Annual General Meeting of Orion Corporation held today, the following decisions were made:

Tiedotteet
21.3.
2023

ORION CORPORATION
STOCK EXCHANGE RELEASE –  OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE

21 March 2023 at 17:45 EET
        

Orion Corporation: Charman of the Nomination Committee changes

Tiedotteet
20.3.
2023

ORION CORPORATION
PRESS RELEASE
20 March 2023 at 09:00 EET              
        
Darolutamide approved for additional prostate cancer indication in China

Tiedotteet
9.3.
2023

ORION CORPORATION
MANAGERS’ TRANSACTIONS
9 MARCH 2023 at 11.30 EET
        

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Tiedotteet
2.3.
2023

ORION CORPORATION
MANAGERS’ TRANSACTIONS
2 MARCH 2023 at 15.00 EET
        

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Tiedotteet
2.3.
2023

ORION CORPORATION
MANAGERS’ TRANSACTIONS
2 MARCH 2023 at 15.00 EET
        

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion

ipo